Figure 1From: Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomesAdjusted mean change from baseline (SE) in total IBDQ score at Week 8. A higher score indicates better quality of life. The ANCOVA model used treatment group as a factor and the baseline value as a covariate. The center was not included in the model. *p = 0.001 compared with placebo (analysis of covariance). BID, twice daily; IBDQ, inflammatory bowel disease questionnaire; SE, standard error.Back to article page